Product Description
Mechanisms of Action: DR Antagonist,5-HT Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Belgium | Israel | South Africa | Spain | Switzerland | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Fundacion Progreso y Salud
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Clotiapine](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Schizophrenia
Phase 3: Schizophrenia|Psychotic Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
INTENSIFY SZ | P4 |
Not yet recruiting |
Schizophrenia |
2026-06-30 |
|
Discontinuation clinical trial in first episode of non-affective psychosis | P3 |
Terminated |
Schizophrenia |
2016-03-21 |
|
NONSTOP | P3 |
Unknown status |
Psychotic Disorders|Schizophrenia |
2015-11-01 |